- Home
- MIN vs SKYE Comparison
MIN vs SKYE Comparison
Compare MIN & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIN | SKYE |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.6M | 44.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MIN | SKYE |
|---|---|---|
| Price | $2.62 | $0.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.75 |
| AVG Volume (30 Days) | 331.0K | ★ 494.0K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 7.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.52 | $0.68 |
| 52 Week High | $2.88 | $5.75 |
Technical Indicators
Market Signals| Indicator | MIN | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 44.61 | 38.82 |
| Support Level | $2.59 | $0.68 |
| Resistance Level | $2.64 | $0.95 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 41.67 | 38.81 |
Price Performance
Historical ComparisonAbout MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.